Quasar Medical, a global contract development and manufacturing organization (CDMO) for minimally invasive medical devices, acquired the Nitinol Design and Development Center in San Diego, California, from Medres International.

The 10,000-sq-ft center, established in 2024, provides nitinol design, development, process engineering, and precision manufacturing for minimally invasive devices. Its capabilities include laser cutting, shape setting, and electropolishing. The acquisition brings dedicated nitinol operations and engineering staff to Quasar and adds design, prototyping, and process optimization capabilities.

The center is about an hour’s drive from Quasar’s facility in Tecate, Mexico, and will have access to the company’s global manufacturing network of 11 locations. Integration will be overseen by Christine Trepanier, senior vice president of technology at Quasar Medical, with Tom Duerig, who introduced nitinol to medical devices as founder of NDC, serving as senior advisor.

“Nitinol is a foundational technology for many of today’s most advanced devices, both in minimally invasive disposables and implantables,” said Alex Wallstein, CEO, Quasar Medical. “This is a significant upgrade of Quasar to a whole new level of expertise.”

“We are confident that under the stewardship of Quasar, the Nitinol Center in San Diego will thrive with dramatically increased resources and customer reach to achieve its full potential,” said Dr. Chris Cheng, CEO and chairman, Medres International.

Quasar Medical has more than 38 years of experience, about 5,000 employees, and 11 locations. The ISO 13485:2016-certified company supplies catheters, balloons, steerable systems, nitinol technologies, electromagnetic sensors, and complex assemblies.

Read further here: https://www.prnewswire.com/news-releases/quasar-medical-acquires-nitinol-design-and-development-center-302839603.html